Lenalidomide Grindeks (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex. This binding changes the complex’s substrate specificity, leading to the ubiquitination and degradation of transcription factors Ikaros and Aiolos. The resulting cascade produces anti‑proliferative, pro‑apoptotic, anti‑angiogenic, and immunomodulatory effects that target malignant plasma cells and modify the tumor microenvironment.

The specific dose of lenalidomide is individualized by the prescribing clinician based on the patient’s diagnosis, disease stage, renal function, and prior therapies. Dosage regimens are outlined in the product’s prescribing information, and any adjustments are made under medical supervision to balance efficacy with safety.

Lenalidomide is classified as a teratogenic agent and is contraindicated in pregnancy. Women of child‑bearing potential must use effective contraception during treatment and for a defined period after discontinuation. Safety data for breastfeeding are insufficient, and the drug is generally not recommended for nursing mothers.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements), and assistance with import documentation.

Lenalidomide belongs to the immunomodulatory drug (IMiD) class, sharing a mechanism with thalidomide but offering greater potency and a more favorable safety profile. Compared with thalidomide, lenalidomide typically causes less peripheral neuropathy and has stronger anti‑angiogenic activity. It is also distinct from proteasome inhibitors such as bortezomib, which act through a different cellular pathway.

Lenalidomide Grindeks should be stored at temperatures below 25 °C (77 °F). Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

The medication is taken orally, usually once daily, with or without food, as directed by the prescribing physician. Swallow the tablet whole with a glass of water; do not crush, split, or chew unless specifically instructed.

Key serious risks include the development of venous thromboembolism, severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, and the possible emergence of secondary primary malignancies. Patients should be monitored closely for signs of clotting, skin changes, or new cancer diagnoses, and any concerning symptoms should be reported immediately.

Lenalidomide is contraindicated in individuals who are pregnant, have known hypersensitivity to the drug or its excipients, or have uncontrolled severe infections. Caution is also advised for patients with significant renal impairment, as dose adjustments may be required, and for those with a history of thromboembolic events without appropriate prophylaxis.